Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib with Cediranib or Ceralasertib in BRCA-Mutated Advanced Breast Cancer
NCT04090567Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2020
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cediranib, ceralasertib in breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2020; status: recruiting.
02
Drugs
cediranibceralasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04090567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04090567.